Scholarlink

Background <p><i>PRAME</i> is a member of the cancer–testis antigen family and exhibits abnormally high expression in various solid tumors. Epigenetic regulation plays a critical role in the development and progression of hepatocellular carcinoma (HCC). Alterations in promoter methylation of specific genes have been widely recognized as valuable biomarkers for predicting cancer risk and assessing prognosis.</p> Objective <p>This study systematically investigated the biological function and clinical relevance of PRAME promoter methylation in HCC.</p> Methods <p>Using data from The Cancer Genome Atlas (TCGA) cohort, we identified methylation-associated prognostic genes and examined the association between <i>PRAME</i> promoter methylation, its mRNA expression levels, overall survival (OS), and clinicopathologic characteristics. We then validated these findings in an independent HCC cohort from Shulan (Hangzhou) Hospital using MethylTarget multiplex gene methylation detection technology. To investigate the potential role of <i>PRAME</i> in vascular invasion and metastasis, we conducted Gene Ontology (GO) enrichment analysis and Gene Set Enrichment Analysis (GSEA) at both histological and cellular levels.</p> Results <p>Analyses across three HCC cohorts consistently showed that the <i>PRAME</i> promoter is generally hypomethylated in tumor tissues, and this hypomethylation was significantly correlated with elevated <i>PRAME</i> mRNA expression. In both the TCGA and Shulan (Hangzhou) Hospital cohorts, <i>PRAME</i> promoter hypomethylation was associated with more advanced clinicopathologic features and shorter OS. Moreover, <i>PRAME</i> promoter methylation status was strongly linked to vascular invasion and distant metastasis in HCC. Further functional analyses revealed significant upregulation of Wnt signaling and cell adhesion–related pathways in tissues with high <i>PRAME</i> expression, a finding corroborated by single-cell RNA sequencing data.</p> Conclusion <p>Hypomethylation of the <i>PRAME</i> promoter is closely associated with poor overall survival, adverse clinicopathologic features, vascular invasion, and metastasis in HCC patients. It plays a pivotal role in regulating gene expression and promoting tumor invasiveness. These findings suggest that <i>PRAME</i> promoter methylation may serve as a promising epigenetic biomarker for prognostic evaluation in HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic value of PRAME gene promoter methylation and expression in hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月9日

查看全文
  • Jintao Zheng,
  • Guoqiang Cao,
  • Jialing Zhao,
  • Longjie Yu,
  • Xiujin Ye,
  • Junru Chen,
  • Haiyang Xie,
  • Jianhui Li,
  • Changku Jia

摘要

Background

PRAME is a member of the cancer–testis antigen family and exhibits abnormally high expression in various solid tumors. Epigenetic regulation plays a critical role in the development and progression of hepatocellular carcinoma (HCC). Alterations in promoter methylation of specific genes have been widely recognized as valuable biomarkers for predicting cancer risk and assessing prognosis.

Objective

This study systematically investigated the biological function and clinical relevance of PRAME promoter methylation in HCC.

Methods

Using data from The Cancer Genome Atlas (TCGA) cohort, we identified methylation-associated prognostic genes and examined the association between PRAME promoter methylation, its mRNA expression levels, overall survival (OS), and clinicopathologic characteristics. We then validated these findings in an independent HCC cohort from Shulan (Hangzhou) Hospital using MethylTarget multiplex gene methylation detection technology. To investigate the potential role of PRAME in vascular invasion and metastasis, we conducted Gene Ontology (GO) enrichment analysis and Gene Set Enrichment Analysis (GSEA) at both histological and cellular levels.

Results

Analyses across three HCC cohorts consistently showed that the PRAME promoter is generally hypomethylated in tumor tissues, and this hypomethylation was significantly correlated with elevated PRAME mRNA expression. In both the TCGA and Shulan (Hangzhou) Hospital cohorts, PRAME promoter hypomethylation was associated with more advanced clinicopathologic features and shorter OS. Moreover, PRAME promoter methylation status was strongly linked to vascular invasion and distant metastasis in HCC. Further functional analyses revealed significant upregulation of Wnt signaling and cell adhesion–related pathways in tissues with high PRAME expression, a finding corroborated by single-cell RNA sequencing data.

Conclusion

Hypomethylation of the PRAME promoter is closely associated with poor overall survival, adverse clinicopathologic features, vascular invasion, and metastasis in HCC patients. It plays a pivotal role in regulating gene expression and promoting tumor invasiveness. These findings suggest that PRAME promoter methylation may serve as a promising epigenetic biomarker for prognostic evaluation in HCC.